Injection drug users' experience with and attitudes toward methadone clinics in Denver, CO

Al-Tayyib, Alia; Koester, Stephen

doi:10.1016/j.jsat.2011.01.009

Cited by 26 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few studies have examined patient perspectives, attitudes, and reasons for leaving methadone (Al-Tayyib & Koester 2011; Reisinger et al 2009; Schwartz et al 2008) and buprenorphine treatment (Egan et al 2011; Winstock, Lintzeris & Lea 2011; Awgu, Magura & Rosenblum 2010; Wallen, Lorman & Gosciniak 2006). Patients’ perspectives are useful in understanding potential barriers to and facilitators of retention and can inform strategies for improving treatment with buprenorphine.…”

Section: Introductionmentioning

confidence: 99%

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study

Teruya

Schwartz

Mitchell

et al. 2014

Journal of Psychoactive Drugs

View full text Add to dashboard Cite

This study examines the barriers and facilitators of retention among patients receiving buprenorphine/naloxone at eight community-based opioid treatment programs across the United States. Participants (n=105) were recruited up to three-and-a-half years after having participated in a randomized clinical trial comparing the effect of buprenorphine/naloxone and methadone on liver function. Semi-structured interviews were conducted with 67 patients provided with buprenorphine/naloxone who had terminated early and 38 patients who had completed at least 24 weeks of the trial. Qualitative data were analyzed using the constant comparison method. Barriers to buprenorphine/naloxone retention that emerged included factors associated with: (1) the design of the clinical trial, (2) negative medication or treatment experience, and (3) personal circumstances. The facilitators comprised: (1) positive experience with the medication, (2) personal determination and commitment to complete, and (3) staff encouragement and support. The themes drawn from interviews highlight the importance of considering patients’ prior experience with buprenorphine/naloxone and methadone, medication preference, personal circumstances, and motivation to abstain from illicit use or misuse of opioids, as these may influence retention. Ongoing education of patients and staff regarding buprenorphine/naloxone, especially in comparison to methadone, and support from staff and peers are essential.

show abstract

Section: Introductionmentioning

confidence: 99%

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study

Teruya

Schwartz

Mitchell

et al. 2014

Journal of Psychoactive Drugs

View full text Add to dashboard Cite

show abstract

“…Despite methadone's efficacy in decreasing opioid use and HIV transmission, methadone remains a treatment option that most opioid-addicts do not use (Al-Tayyib and Koester, 2011; Kleber, 2008; Peterson et al, 2010; Schwartz et al, 2008; Zaller, Bazazi, Velazquez, and Rich, 2009). …”

mentioning

confidence: 99%

The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: A randomized controlled trial

Holtyn

Koffarnus

DeFulio

et al. 2014

Preventive Medicine

View full text Add to dashboard Cite

Objective Determine if employment-based reinforcement can increase methadone treatment engagement and drug abstinence in out-of-treatment injection drug users. Method This study was conducted from 2008–2012 in a therapeutic workplace in Baltimore, MD. After a 4-week induction, participants (N=98) could work and earn pay for 26 weeks and were randomly assigned to Work Reinforcement, Methadone & Work Reinforcement, and Abstinence, Methadone & Work Reinforcement conditions. Work Reinforcement participants had to work to earn pay. Methadone & Work Reinforcement, and Abstinence, Methadone, & Work Reinforcement participants had to enroll in methadone treatment to work and maximize pay. Abstinence, Methadone, & Work Reinforcement participants had to provide opiate- and cocaine-negative urine samples to maximize pay. Results Most participants (92%) enrolled in methadone treatment during induction. Drug abstinence increased as a graded function of the addition of the methadone and abstinence contingencies. Abstinence, Methadone & Work Reinforcement participants provided significantly more urine samples negative for opiates (75% versus 54%) and cocaine (57% versus 32%) than Work Reinforcement participants. Methadone & Work Reinforcement participants provided significantly more cocaine-negative samples than Work Reinforcement participants (55% versus 32%). Conclusion The therapeutic workplace can promote drug abstinence in out-of-treatment injection drug users.

show abstract

“…However, research on community drug treatment emphasize that it is not an easy choice (e.g. Al-Tayyib and Koester, 2011;Hunt and Barker, 1999;Koester et al, 1999), and our study shows that this is no less the case when treatment is located in a prison setting. Rather, the routes into drug treatment are plenty and in many instances accidental.…”

Section: Reasons To Start -And Stay -In Treatmentmentioning

confidence: 47%

Inmates’ perspectives on prison drug treatment

et al. 2015

View full text Add to dashboard Cite

The purpose of this article is to employ a user-perspective on prison drug treatment. Based on data from 32 in-depth qualitative interviews with inmates and three months of observational studies in three Danish prisons, the article examines how drug treatment in prison is experienced and strategically approached by enrolled inmates. The analysis shows the broad range of reasons for entering as well as staying in treatment during imprisonment, including how the prison setting influences and constrains inmates' experiences in different ways. By employing a user-perspective the article follows the research tradition, beginning in the 1990s, of including drug users' perspectives on treatment. It adds important information to the drug treatment literature on issues such as organization, social relations and output of drug treatment. Including a user-perspective, we were able to uncover aspects and experiences of treatment services that differ from other actors in the field, e.g. counsellors, medical doctors, nurses, politicians, and officers. A user-perspective also challenges our understanding of what is at play in drug treatment as well as treatment in prisons.

show abstract

Injection drug users' experience with and attitudes toward methadone clinics in Denver, CO

Cited by 26 publications

References 30 publications

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study

Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study

The therapeutic workplace to promote treatment engagement and drug abstinence in out-of-treatment injection drug users: A randomized controlled trial

Inmates’ perspectives on prison drug treatment

Contact Info

Product

Resources

About